Enanta Pharmaceuticals, Inc.

As of November 25, 2020, Enanta Pharmaceuticals, Inc. is considered overvalued and risky due to its negative P/E ratio, poor returns on capital, and underperformance relative to peers, with a 1-year return of -31.17% compared to the S&P 500's 17.14%.

As of November 25, 2020, Enanta Pharmaceuticals, Inc. has been downgraded to a risky valuation grade due to being overvalued with negative financial metrics, including a Price to Book Value of 1.71 and poor returns, while its stock has underperformed significantly compared to the S&P 500.

As of May 15, 2025, Enanta Pharmaceuticals, Inc. is in a mildly bearish trend due to bearish daily moving averages, despite some mixed signals from weekly indicators.

As of March 2022, the management team of Enanta Pharmaceuticals, Inc. includes Dr. Bruce Carter (Independent Non-Executive Chairman), Dr. Jay Luly (President and CEO), and several Independent Directors: Mr. Mark Foletta, Dr. George Golumbeski, Ms. Kristine Peterson, and Dr. Lesley Russell. They oversee the company's strategic direction and operations.

Enanta Pharmaceuticals, Inc. is a biotechnology company focused on developing small molecule drugs for viral infections and liver diseases. As of March 2025, it reported net sales of $15 million and a net loss of $23 million, with a market cap of $150.70 million.

As of Jun 18, Enanta Pharmaceuticals, Inc. has a market capitalization of 150.70 million, with net sales of 64.47 million and a net loss of 96.41 million over the latest four quarters. Shareholder's funds are 128.81 million, and total assets amount to 390.80 million.